AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02396771 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterine Massage
Description: The massage will be performed as follows: palpating the uterine fundus, manually stimulating the fundus and the whole body of the uterus using fingers and palms steadily and repetitively.
Study NCT02396771 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterine Compression
Description: The sustained uterine compression will be performed as follows: placing one hand in the vagina and pushing against the body of the uterus while the other hand compresses the fundus from above through the abdominal wall.
Study NCT03626636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risuteganib
Description: Subjects injected intravitreally with 1.0mg of Luminate®
Study NCT03626636 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham
Description: Sham injection
Study NCT00395291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0677
Description: The dosage of the drug is 25mg, subjects will take one pill a day for about 30 days.
Study NCT00395291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT03429673 — intervention group
Intervention type: PROCEDURE
Intervention: Surgeries
Description: Lobectomy or segment/wedge dissection
Study NCT01214304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Essential Lavender Oil
Description: Aromatherapy with essential lavender oil will be initiated 5 minutes prior to the procedure and continued until the conclusion of the procedure (patient dressed and ready to leave the room). The essential lavender oil and will be administered by fan diffuser.
Study NCT01214304 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lavender Scent
Description: Aromatherapy with a fake lavender scent (placebo) will be initiated 5 minutes prior to the procedure and continued until the conclusion of the procedure (patient dressed and ready to leave the room). The fake lavender scent will be administered by fan diffuser.
Study NCT00420004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: 3-mg and 6-mg tablets
Study NCT00420004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT00420004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00420004 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00420004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: 10-mg capsules
Study NCT00309140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: 500 milligrams (mg), oral, daily, six 42-day cycle and subsequent cycles or until participants met study discontinuation criteria of progressive disease or unacceptable toxicity
Study NCT01223885 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Camel's milk
Description: Patients with proved cow's milk allergy who have negative prick skin tests to came's milk will be administered gradually increased doses of pasteurized camel's milk at 30 minute intervals
Study NCT05901363 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde cholangiopancreatography plus laparoscopic cholecystectomy
Description: laparoscopic removal of gallbladder and endoscopic extraction of common bile duct stones
Study NCT05901363 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: aparoscopic common bile duct exploration and laparoscopic cholecystectomy
Description: laparoscopic removal of gallbladder and laparoscopic extraction of common bile duct stones
Study NCT01381003 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: pCCLchimGp91s lentiviral vector transduced CD34+ cells infusion
Description: pCCLchimGp91s lentiviral vector transduced CD34+ cells will be infused in a volume of 50-100 mls intravenously over 30-45 minutes
Study NCT00785421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enoxaparin
Description: Patients receive GFFC +/- LMWH (gemcitabine 1 g/m2 (30 min), cisplatin 30 mg/m2 (90 min), 5-fluorouracil 750 mg/m2 (24 h), folinic acid 200 mg/m2 (30 min), d1, 8; q3w +/- Enoxaparin 1mg/kg daily s.c.). Pts with KPS \< 80 % and increased creatinin plasma levels (>1.3 mg/dl) receive the current standard therapy (gemcitabine 1 g/m2 (30 min), d1, 8, 15; q4w) +/- LMWM +/- Enoxaparin 1mg/kg daily s.c. After 12 weeks of initial chemotherapy all patients who have not progressed received the standard therapy (gemcitabine mono) +/- Enoxaparin 40mg/d s.c.
Study NCT00785421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy with LMWH - enoxaparin
Description: 1-12 weeks: enoxaparin 1g/m², s.c. 12-PD or event: enoxaparin 0,4g s.c.
Study NCT00785421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: only chemotherapy
Description: observation, no treatment with LMWH
Study NCT02460913 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture session of 20 to 30 minutes. Treatment protocols were determined through review of major clinical manuals and textbooks, literature review, and a panel of specialist acupuncturists from Chinese medicine backgrounds.
Study NCT02460913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine titration
Description: Patients in this group received IV titrated morphine. Morphine was prepared onsite and diluted in a manner to obtain a dose of 1mg in each ml of normal saline. The initial dose was 0.1 mg per kg and a titration dose of 0.05 mg per Kg was repeated every 5 minutes until reaching objective. The maximum allowed dose was 1.5 mg/kg.
Study NCT03638908 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fluoxetine
Study NCT00100230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docosahexaenoic acid OR corn/soy oil placebo
Description: daily intake of DHA based on body weight or corn/soy oil placebo(oil not containing DHA; 4 year trial
Study NCT00100230 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: docosahexaenoic acid OR corn/soy oil placebo
Description: daily intake of DHA based on body weight or corn/soy oil placebo(oil not containing DHA; 4 year trial
Study NCT02269176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose of telmisartan
Study NCT02269176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose of telmisartan
Study NCT02514447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Study NCT02635555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: 100 mcg of phenylephrine or 5 mg ephedrine given as deemed necessary for treating episodes of hypotension.
Study NCT02635555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: 100 mcg of phenylephrine or 5 mg ephedrine given as deemed necessary for treating episodes of hypotension.
Study NCT03273192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: A single 40-mg dose of Adalimumab is administered subcutaneously to all the subjects.
Study NCT03273192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: A single 40-mg dose of Adalimumab is administered subcutaneously to all the subjects.
Study NCT04273217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-1
Description: Single dose, administered by IV infusion (volume: 250 mL)
Study NCT04273217 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sterile saline. Administered by IV infusion (volume: 250 mL)
Study NCT05308745 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Yakult®
Description: Fermented milk drink containing over 6.5×10\^9 CFUs of L. casei Shirota/65 ml
Study NCT05308745 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taste, appearance, component, and number of calories are the same as Yakult®, non-fermented milk product
Study NCT01843751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: buprenorphine/naloxone
Description: Buprenorphine/naloxone (Suboxone) is considered a well-investigated, highly effective medication-assisted treatment for opiate dependence, but it may only be supervised through the few specialist treatment facilities in the state, or by physicians who have historically been less likely to offer this service. The effectiveness of community physician treatment supervision has not been tested for those in the criminal justice system.
Study NCT01843751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine/naloxone
Description: Buprenorphine/naloxone (Suboxone) is considered a well-investigated, highly effective medication-assisted treatment for opiate dependence, but it may only be supervised through the few specialist treatment facilities in the state, or by physicians who have historically been less likely to offer this service. The effectiveness of community physician treatment supervision has not been tested for those in the criminal justice system.
Study NCT00527007 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: External cooling
Description: External cooling
Study NCT02354079 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: hypobetalipoproteinemia genetic and genotypic screening
Study NCT01548092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adipose-derived stem cells without expanded
Description: Administration will be intralesional injection of cells suspension. They will be placed into fistula walls
Study NCT01847222 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SANGUINATE™
Description: PEG-bHb-CO
Study NCT01847222 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Solution
Description: Placebo
Study NCT03353493 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBCT
Description: Mindfulness-Based Cognitive Therapy (MBCT) is an 8 week manualised group intervention. MBCT will be delivered according to the manual by Segal, Williams \& Teasdale (2013).
Study NCT03353493 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TAU
Description: Treatment as usual (TAU)
Study NCT03353493 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: TAU
Description: Treatment as usual (TAU)
Study NCT02007018 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy
Description: Prevena™ Incision Management System (PIMS) (Kinetic Concepts Inc. (KCI), San Antonio, TX) is an incisional vacuum assisted closure (PIMS) device intended to manage the environment of surgical incisions that continue to drain following sutured or stapled closure by maintaining a closed environment and removing exudates via the application of negative pressure wound therapy The PIMS applies continuous pressure to the closed surgical site at 125 mm Hg and is attached to a 45 mL canister for collection of exudate.
Study NCT02007018 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care of Surgical Wound
Description: Patients will receive pre-operative antibiotics consisting of 1g cefazolin (or in the case of an allergy, an alternative e.g. ciprofloxacin/vancomycin) and 500 mg metronidazole given intravenously within the 30 minute prior to beginning the operative procedure. In cases extending > 4 hours, a second dose of each of the antibiotics will be administered. Hair at the operative site will be removed, if required, immediately prior to the skin incision using electric clippers. The abdomen will be prepped using 2% Chlorhexidiene solution (or 10% povidone if allergic). After closure of the skin, the surgical wound will be covered with a sterile adhesive dressing (Tegaderm), which will remain in place until the morning of post-operative day (POD)#2, unless saturated, in which case it is standard practice to change the dressing if the physician is in agreement. On POD#2, the surgical team will remove the initial dressing and daily dressing changes with standard gauze will be initiated.
Study NCT02007018 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care of Surgical Wound
Description: Patients will receive pre-operative antibiotics consisting of 1g cefazolin (or in the case of an allergy, an alternative e.g. ciprofloxacin/vancomycin) and 500 mg metronidazole given intravenously within the 30 minute prior to beginning the operative procedure. In cases extending > 4 hours, a second dose of each of the antibiotics will be administered. Hair at the operative site will be removed, if required, immediately prior to the skin incision using electric clippers. The abdomen will be prepped using 2% Chlorhexidiene solution (or 10% povidone if allergic). After closure of the skin, the surgical wound will be covered with a sterile adhesive dressing (Tegaderm), which will remain in place until the morning of post-operative day (POD)#2, unless saturated, in which case it is standard practice to change the dressing if the physician is in agreement. On POD#2, the surgical team will remove the initial dressing and daily dressing changes with standard gauze will be initiated.
Study NCT03687853 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrahepatic Arterial Infusion
Description: Intrahepatic Arterial Infusion chemotherapy is one of the most widely used liver tumor treatments.
Study NCT02226406 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A: Chair - Leg Cycle ergometer
Study NCT02226406 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: B: Chair - Arm Cycle ergometer
Study NCT02226406 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: C: Walk in place
Study NCT03256214 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Closed suction system
Description: In mechanically ventilated patients, intratracheal secretions were aspirated with closed suction systems to compare the pulmonary and cardiovascular parameters (Peak Pressure, Resistance, and Pressure Plateau, Heart Rate and Mean, Diastolic, and Systolic Pressures) with open suction system.
Study NCT03256214 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open suction system
Description: In mechanically ventilated patients, intratracheal secretions were aspirated with open suction systems to compare the pulmonary and cardiovascular parameters (Peak Pressure, Resistance, and Pressure Plateau, Heart Rate and Mean, Diastolic, and Systolic Pressures) with closed suction system.
Study NCT02781922 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous cardiac stem cells (JRM-001)
Description: 3x 10\^5 cells/kg, single treatment
Study NCT02809456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorandil
Description: oral intake
Study NCT02809456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicorandil
Description: oral intake
Study NCT01503268 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of implantable loop recorder
Description: An implantable loop recorder (ILR) will be used to assess atrial fibrillation(AF) before and after DCCV or ablation, unless there is a pre-existing ILR or permanent pacemaker capable of continuous monitoring for occurrence of AF.
Study NCT01503268 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous ablation of atrial fibrillation
Description: Catheter-based percutaneous ablation of atrial fibrillation
Study NCT01503268 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical ablation of atrial fibrillation
Description: Minimally-invasive thoracoscopic surgical ablation of atrial fibrillation
Study NCT01170507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3 1000 IU orally daily for 5 months
Study NCT01170507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3 3000 IU orally daily for 5 months
Study NCT01170507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3 5000 IU orally daily for 5 months
Study NCT01170507 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo orally daily for 5 months
Study NCT01434069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOM230C LAR
Description: Participants will be given one LAR dose injected into the muscle of the buttocks by a study nurse about once every 28 days until unacceptable toxicity or progression of the disease.
Study NCT02269176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose of losartan
Study NCT01434069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI Infusion
Description: Standard therapy of FOLFIRI
Study NCT04484792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: green tea mouthwash
Description: green tea bags in 100 ml warm water for 5 min
Study NCT04484792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: green tea mouthwash
Description: , in Group B its prepared by soaking tea bags in 100 ml hot water followed by ice addition.
Study NCT04484792 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Plain water
Study NCT02279901 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine Education
Description: Emmi Solutions produces Web-based, simple to understand, healthcare related educational programs. These programs are interactive sessions that last about 15 minutes, educating patients on the risk of OSA and assisting in preparing patients for procedures. Two such programs will be sent to patients at preset intervals over the duration of the study:~1. OSA program~2. CPAP program~Links to each of these programs are emailed to the patient and date of birth needs to be verified before the program will start. The programs ask the patient for feedback at regular intervals and provide opportunities throughout to make notes or write down questions that can be later printed. These programs are already approved for clinical use within Kaiser Permanente which has a contract with the vendor.
Study NCT02279901 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IVR
Description: Interactive Voice Response (IVR) is a protocol in which automated messages are delivered via e-mail, text or phone to patients to provide feedback regarding their CPAP use, intended to improve therapy adherence. The basic protocol involves the use of CPAP devices that wirelessly send usage data to a cloud platform. Automated algorithms will assess the usage data and send messages to the patient when there is suboptimal usage or excessive leak, or to provide encouragement for successful use.~Specifically, we will use CPAP devices with built-in modems which will send usage data via cellular network to cloud-based platforms that will automatically analyze the usage data and send the automated messages. Patients also can track their own therapy information through the platform.
Study NCT03838640 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EPIQ 5
Description: As described in summary Trade name of the device Philips EPIQ 5
Study NCT04236011 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC012F injection
Description: GC012F injection is a autologous dual CAR-T targeted BCMA and CD19. A single infusion of CART cells will be administered intravenously.
Study NCT00490854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Insulin Inhalation Powder
Description: patient specific, inhaled, at meals, 76 weeks
Study NCT00490854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neutral protamine hagedorn insulin
Description: patient specific dose, injected, daily, 76 weeks
Study NCT00176826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Infusion of hematopoietic stem cells (bone marrow, cord blood, peripheral blood stem cells) following myeloablative conditioning regimen.
Study NCT00176826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myeloablative conditioning regimen
Description: Busulfan intravenously for 4 days followed by cyclophosphamide intravenously for 4 days. Rabbit ATG is given intravenously for 4 doses pre-transplant.
Study NCT02423577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-3 dry powder
Description: FF-3 dry powder administered by nasal inhalation
Study NCT02423577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo dry powder administered by nasal inhalation
Study NCT01946425 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® Quadrivalent Influenza Virus Vaccine, No Preservative
Description: 0.25 mL, Intramuscular (Pediatric Dose, 2013-2014 formulation)
Study NCT01946425 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® Quadrivalent Influenza Virus Vaccine, No Preservative
Description: 0.5 mL, Intramuscular (2013-2014 formulation)
Study NCT02216188 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AFFITOPE® PD01A
Description: s.c. injection
Study NCT02216188 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Untreated control group
Study NCT02786342 — intervention group
Intervention type: PROCEDURE
Intervention: blood sample collection
Study NCT03781128 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lysergic Acid Diethylamide
Description: 100 µg, per os, 3 times within 3 weeks
Study NCT03781128 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: placebo in an identical-looking vial as LSD, per os, 3 times within 3 weeks
Study NCT02269176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High dose of losartan